TNFSF11 and Duchenne muscular dystrophy: The ability of anti-RANKL therapy to restore muscle function has profound implications for DMD patients because its use offers the possibility of using one drug to improve skeletal muscle function and prevent steroid/muscle function-induced bone loss.